These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31325786)

  • 1. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
    Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors.
    Chu KF; Song JS; Chen CT; Yeh TK; Hsieh TC; Huang CY; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC
    Bioorg Chem; 2019 Mar; 83():520-525. PubMed ID: 30469144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors.
    Zhao X; Sun B; Zheng H; Liu J; Qian L; Wang X; Lou H
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2201-2205. PubMed ID: 29764742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
    Haider K; Pathak A; Rohilla A; Haider MR; Ahmad K; Yar MS
    Eur J Med Chem; 2019 Dec; 184():111773. PubMed ID: 31630053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
    ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
    [No Abstract]   [Full Text] [Related]  

  • 6. Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Xu B; Feng Y; Peng K; Xu G; Du J; Zhang L; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6877-81. PubMed ID: 19896374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Ohtake Y; Sato T; Kobayashi T; Nishimoto M; Taka N; Takano K; Yamamoto K; Ohmori M; Yamaguchi M; Takami K; Yeu SY; Ahn KH; Matsuoka H; Morikawa K; Suzuki M; Hagita H; Ozawa K; Yamaguchi K; Kato M; Ikeda S
    J Med Chem; 2012 Sep; 55(17):7828-40. PubMed ID: 22889351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
    Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
    J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors.
    Yamamoto Y; Kawanishi E; Koga Y; Sakamaki S; Sakamoto T; Ueta K; Matsushita Y; Kuriyama C; Tsuda-Tsukimoto M; Nomura S
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5641-5. PubMed ID: 23999047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition.
    Ng WL; Li HC; Lau KM; Chan AKN; Lau CB; Shing TKM
    Sci Rep; 2017 Jul; 7(1):5581. PubMed ID: 28717146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes.
    Kong YK; Song KS; Jung ME; Kang M; Kim HJ; Kim MJ
    Bioorg Med Chem Lett; 2022 Jan; 56():128466. PubMed ID: 34813882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 6-deoxydapagliflozin as a highly potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Zhang L; Wang Y; Xu H; Shi Y; Liu B; Wei Q; Xu W; Tang L; Wang J; Zhao G
    Med Chem; 2014 May; 10(3):304-17. PubMed ID: 24059684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
    Wan HX; Shen JK
    Yao Xue Xue Bao; 2012 Jun; 47(6):716-24. PubMed ID: 22919717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN
    J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
    Takasu T; Yokono M; Tahara A; Takakura S
    Biol Pharm Bull; 2019; 42(3):507-511. PubMed ID: 30828082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
    Cai W; Jiang L; Xie Y; Liu Y; Liu W; Zhao G
    Med Chem; 2015; 11(4):317-28. PubMed ID: 25557661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of thiophene-C-glucosides as sodium-dependent glucose cotransporter 2 inhibitors.
    Sakamaki S; Kawanishi E; Koga Y; Yamamoto Y; Kuriyama C; Matsushita Y; Ueta K; Nomura S
    Chem Pharm Bull (Tokyo); 2013; 61(10):1037-43. PubMed ID: 24088695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2.
    Yuan MC; Yeh TK; Chen CT; Song JS; Huang YC; Hsieh TC; Huang CY; Huang YL; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC
    Eur J Med Chem; 2018 Jan; 143():611-620. PubMed ID: 29216560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice.
    Li Z; Murakoshi M; Ichikawa S; Koshida T; Adachi E; Suzuki C; Ueda S; Gohda T; Suzuki Y
    FEBS Open Bio; 2020 Dec; 10(12):2761-2770. PubMed ID: 33098615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.